<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730795</url>
  </required_header>
  <id_info>
    <org_study_id>692342/001</org_study_id>
    <secondary_id>CCTB001-01</secondary_id>
    <nct_id>NCT00730795</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults</brief_title>
  <official_title>A Phase I Open Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Recombinant Mycobacterium Tuberculosis Vaccine, Mtb72F With AS02A Adjuvant, When Administered Intramuscularly to Healthy PPD-Negative Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Corixa Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This Phase I study will evaluate the safety and immunogenicity of two doses GSK Biologicals'&#xD;
      candidate TB vaccine (692342) according to a 0, 1, 2 months schedule in PPD-negative adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose limiting toxicity</measure>
    <time_frame>From study start up to Day 56.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>During the entire study period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>At each visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory measurements of serum chemistry and hematology</measure>
    <time_frame>At study start, prior to each vaccination and 1 and 6 months after dose 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Resting vital signs (blood pressure, pulse, temperature)</measure>
    <time_frame>At study start, prior to each vaccination and 1 and 6 months after dose 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Chest X-ray findings</measure>
    <time_frame>At study start and study end</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of T cell and antibody responses to the fusion protein and to each of the three Mycobacterium tuberculosis antigen domains.</measure>
    <time_frame>Prior to each vaccination and 1 and 6 months after dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of PPD skin reactivity</measure>
    <time_frame>At study start and study end</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Tuberculosis (TB)</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving the low-dose antigen candidate TB vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving the high-dose antigen candidate TB vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK's candidate Mycobacterium tuberculosis vaccine 692342</intervention_name>
    <description>Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female between 18 and 40 years of age at the time of screening&#xD;
&#xD;
          -  Negative PPD skin test at screening.&#xD;
&#xD;
          -  Subjects must have chest X-ray showing no evidence of pulmonary pathology.&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening, must not be breast-feeding and are required to use adequate contraception&#xD;
             from enrolment till 1 month after dose 3.&#xD;
&#xD;
          -  Screening laboratory values must be within the laboratory normal ranges.&#xD;
&#xD;
          -  Negative for human immunodeficiency virus-1 and 2 (HIV 1/2) antibody, hepatitis B&#xD;
             surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.&#xD;
&#xD;
          -  Subjects must give written informed consent.&#xD;
&#xD;
          -  Subjects must be willing to make all evaluation visits, be readily reachable by&#xD;
             telephone or personal contact by the study site personnel and have a permanent&#xD;
             address.&#xD;
&#xD;
          -  Subjects' resting seated vital signs must be within the protocol-defined ranges.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of prior Bacillus Calmette-Gu√©rin (BCG) vaccinations.&#xD;
&#xD;
          -  History of documented exposure to Mycobacterium tuberculosis.&#xD;
&#xD;
          -  History of previous administration of experimental Mycobacterium tuberculosis vaccines&#xD;
             or previous exposure to experimental products containing components of the&#xD;
             experimental vaccine.&#xD;
&#xD;
          -  History of employment in a healthcare facility in a capacity that had direct or&#xD;
             indirect contact with TB patients.&#xD;
&#xD;
          -  Administration of any immunoglobulins or any immunotherapy within the 3 months&#xD;
             preceding the first dose of study vaccination, and/or any blood products within the 4&#xD;
             months preceding HIV screening, or planned administrations during the study period.&#xD;
&#xD;
          -  Use of St. John's Wort within six months of the Day 0 visit or planned administrations&#xD;
             during the study period.&#xD;
&#xD;
          -  Participation in another experimental protocol and/or receipt of any investigational&#xD;
             products within 30 days prior to Day 0.&#xD;
&#xD;
          -  History of autoimmune disease or causes of immunosuppressive states.&#xD;
&#xD;
          -  History of any acute or chronic illness or medication that, in the opinion of the&#xD;
             Investigator, may interfere with the evaluation of the safety or immunogenicity of the&#xD;
             vaccine.&#xD;
&#xD;
          -  History of significant psychiatric illness.&#xD;
&#xD;
          -  Current drug or alcohol abuse&#xD;
&#xD;
          -  History of previous anaphylaxis or severe allergic reaction to vaccines or any other&#xD;
             allergen.&#xD;
&#xD;
          -  Subjects who are, in the opinion of the investigator, at significantly increased risk&#xD;
             of non-cooperation with requirements of the study protocol.&#xD;
&#xD;
          -  Any chronic drug therapy to be continued during the study period, with the exception&#xD;
             of vitamins and/or dietary supplements (including mineral preparations such as calcium&#xD;
             carbonate), herbal medications except St. John's Wort, birth control pills,&#xD;
             anti-histamines for seasonal allergies, SSRIs (e.g. Prozac, Zoloft, Paxil), NSAIDs&#xD;
             (e.g. aspirin, ibuprofen), and acetominophen.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days total) of immunosuppressants or&#xD;
             other immune modifying drugs within six months prior to the first vaccine dose.&#xD;
&#xD;
          -  History of chronic or intermittently recurring illnesses such as migraine headaches,&#xD;
             diabetes, heart disease, and asthma.&#xD;
&#xD;
          -  Current administration of anti-TB prophylaxis or therapy.&#xD;
&#xD;
          -  History of administration of a live attenuated virus vaccine within 30 days of&#xD;
             enrollment.&#xD;
&#xD;
          -  History of administration of a subunit or killed vaccine within 14 days of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>9843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>August 7, 2008</last_update_submitted>
  <last_update_submitted_qc>August 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Isabelle Harpigny</name_title>
    <organization>GSK Biologicals</organization>
  </responsible_party>
  <keyword>Tuberculosis vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

